Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.

Saved in:
Bibliographic Details
Title: Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Authors: Namboodiri HV; Department of Biology, Locus Pharmaceuticals, Inc, Four Valley Square, 512 East Township Line Rd,Blue Bell, Pennsylvania 19422, USA. vnamboodiri@ansarisbio.com, Bukhtiyarova M, Ramcharan J, Karpusas M, Lee Y, Springman EB
Source: Biochemistry [Biochemistry] 2010 May 04; Vol. 49 (17), pp. 3611-8.
Publication Type: Comparative Study; Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 0370623 Publication Model: Print Cited Medium: Internet ISSN: 1520-4995 (Electronic) Linking ISSN: 00062960 NLM ISO Abbreviation: Biochemistry Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1520-4995
DOI:10.1021/bi100070r